Paul W Denton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8358217/publications.pdf

Version: 2024-02-01

186265 138484 4,167 63 28 58 citations h-index g-index papers 67 67 67 3974 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nature Medicine, 2006, 12, 1316-1322.	30.7	590
2	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	4.7	445
3	Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice. PLoS Medicine, 2008, 5, e16.	8.4	291
4	Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. Journal of Experimental Medicine, 2007, 204, 705-714.	8.5	256
5	Generation of HIV Latency in Humanized BLT Mice. Journal of Virology, 2012, 86, 630-634.	3.4	180
6	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV,the, 2016, 3, e463-e472.	4.7	159
7	Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice. PLoS ONE, 2010, 5, e8829.	2.5	148
8	Humanized mouse models of HIV infection. AIDS Reviews, 2011, 13, 135-48.	1.0	135
9	One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates. Journal of Virology, 2011, 85, 7582-7593.	3.4	133
10	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 64, 1686-1695.	5.8	122
11	Functional and Phenotypic Characterization of the Humanized BLT Mouse Model. Current Topics in Microbiology and Immunology, 2008, 324, 149-165.	1.1	113
12	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. PLoS Pathogens, 2014, 10, e1003872.	4.7	101
13	Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 5705-5712.	3.4	100
14	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 ⁺ T Cells. Journal of Virology, 2016, 90, 4441-4453.	3.4	94
15	The size and culturability of patient-generated SARS-CoV-2 aerosol. Journal of Exposure Science and Environmental Epidemiology, 2022, 32, 706-711.	3.9	87
16	IL-2 receptor \hat{I}^3 -chain molecule is critical for intestinal T-cell reconstitution in humanized mice. Mucosal Immunology, 2012, 5, 555-566.	6.0	85
17	Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice. PLoS Pathogens, 2012, 8, e1002732.	4.7	82
18	Novel humanized murine models for HIV research. Current HIV/AIDS Reports, 2009, 6, 13-19.	3.1	66

#	Article	IF	CITATIONS
19	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Aids, 2019, 33, 1315-1325.	2.2	66
20	Broad activation of latent HIV-1 in vivo. Nature Communications, 2016, 7, 12731.	12.8	65
21	Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. Journal of Reproductive Immunology, 2011, 88, 195-203.	1.9	60
22	Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends in Microbiology, 2012, 20, 268-274.	7.7	60
23	Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology, 2012, 9, 44.	2.0	60
24	Cryptopatches Are Essential for the Development of Human GALT. Cell Reports, 2013, 3, 1874-1884.	6.4	58
25	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. PLoS ONE, 2013, 8, e60024.	2.5	54
26	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. Journal of Virology, 2019, 93, .	3.4	49
27	Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. Nature Communications, 2018, 9, 3525.	12.8	37
28	The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunology, 2018, 11, 449-461.	6.0	31
29	ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. Journal of Clinical Investigation, 2016, 126, 892-904.	8.2	30
30	In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis. Retrovirology, 2013, 10, 125.	2.0	26
31	Histone Deacetylase Inhibitor Romidepsin Inhibits <i>De Novo</i> HIV-1 Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 3984-3994.	3.2	26
32	Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection. Mucosal Immunology, 2020, 13, 753-766.	6.0	24
33	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. EBioMedicine, 2019, 45, 328-340.	6.1	22
34	Hypogammaglobulinemia in BLT Humanized Mice – An Animal Model of Primary Antibody Deficiency. PLoS ONE, 2014, 9, e108663.	2.5	20
35	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. Aids, 2016, 30, 713-721.	2.2	19
36	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Inflammatory Responses. MSphere, 2018, 3, .	2.9	17

3

#	Article	IF	CITATIONS
37	Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs. Journal of Controlled Release, 2019, 294, 298-310.	9.9	17
38	Susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease in BALB/cAnNCr mice is related to absence of a CD4+ T-cell subset. Multiple Sclerosis Journal, 2002, 8, 469-474.	3.0	15
39	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. Journal of Translational Medicine, 2016, 14, 44.	4.4	15
40	Long-Acting, Potent Delivery of Combination Antiretroviral Therapy. ACS Macro Letters, 2018, 7, 587-591.	4.8	15
41	Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues. Frontiers in Microbiology, 2019, 10, 1956.	3.5	14
42	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. Journal of Virus Eradication, 2019, 5, 133-137.	0.5	13
43	Immune checkpoints and the HIV-1 reservoir: proceed with caution. Journal of Virus Eradication, 2016, 2, 183-6.	0.5	12
44	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	10
45	The role of miR-29a in HIV-1 replication and latency. Journal of Virus Eradication, 2017, 3, 185-191.	0.5	10
46	Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. Aids, 2018, 32, 1793-1802.	2.2	10
47	Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Scientific Reports, 2017, 7, 41098.	3.3	8
48	Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice. PLoS ONE, 2020, 15, e0241375.	2.5	7
49	<scp>cAlMP</scp> administration in humanized mice induces a chimerizationâ€levelâ€dependent <scp>STING</scp> response. Immunology, 2019, 157, 163-172.	4.4	6
50	Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection. Journal of Visualized Experiments, 2020, , .	0.3	6
51	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation. Journal of Virus Eradication, 2019, 5, 133-137.	0.5	6
52	The role of miR-29a in HIV-1 replication and latency. Journal of Virus Eradication, 2017, 3, 185-191.	0.5	5
53	Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection. Open Forum Infectious Diseases, 2018, 5, ofy006.	0.9	4
54	Predicting Cognitive Rehabilitation Needs in Patients with Central Nervous System Infections Using Montreal Cognitive Assessment. SN Comprehensive Clinical Medicine, 2021, 3, 1350-1357.	0.6	3

#	Article	IF	CITATIONS
55	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. Aids, 2017, 31, 2311-2313.	2.2	2
56	Modest de novo Reactivation of Single HIV-1 Proviruses in Peripheral CD4+ T Cells by Romidepsin. Frontiers in Virology, 2021, 1 , .	1.4	1
57	Impact of the Mouse IL- $2R\hat{l}^3$ Chain on Lymphoid Tissue Development and Human Reconstitution in Immunodeficient Mice. , 2014, , 61-73.		1
58	Helminth products modulate innate immune recognition of nucleic acids in systemic lupus erythematosus. Lupus, 2022, 31, 415-423.	1.6	1
59	HIV cure trial mergers: Spotlighting the epigenetics of latency reversal. EBioMedicine, 2022, 79, 104012.	6.1	1
60	CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy. Frontiers in Cellular and Infection Microbiology, 0, 12 , .	3.9	1
61	CD8 + T cells reduce in vitro interferon-g production in Theiler's murine encephalomyelitis virus-induced demyelinating disease model. Multiple Sclerosis Journal, 2004, 10, 370-375.	3.0	O
62	Poor compliance with an antibiotic directive—A call for intensified monitoring. International Journal of Infectious Diseases, 2021, 104, 474-478.	3.3	0
63	Vaginal and Rectal HIV Transmission in Humanized Mice. , 2014, , 235-245.		O